Switch to Dark theme

References

Coronavirus: WHO warns against pandemic complacency after recent vaccine progress. 2020. https://tinyurl.com/wsm8za3w (accessed February 2021)
Polack F, Thomas S, Kitchin N Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383:2603-2615
Voysey M, Clemens S, Madhi S Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397:99-111
Baden L, El Sahly H, Essink B Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384:403-416
Department of Health and Social Care. Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines. 2021. https://tinyurl.com/k9hf2uk8 (accessed February 2021)

Letters to the Editor

From Volume 48, Issue 3, March 2021 | Page 242

Authors

Kiran Singh

Dental Core Trainee in Oral and Maxillofacial Surgery, Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation Trust

Articles by Kiran Singh

Sanford Grossman

Specialty Registrar in Oral Surgery, Torbay Hospital, Torbay and South Devon NHS Foundation Trust

Articles by Sanford Grossman

Kevin McMillan

Specialist Registrar, Oral & Maxillofacial Department, University Hospital Birmingham Foundation NHS Trust

Articles by Kevin McMillan

Article

There has been growing concern that, with the recent lockdown announced on 4 January 2021, the nation may be at risk of pandemic complacency,1 following an arduous and protracted series of frequently changing restrictions and lockdowns.

With the recent advent and widespread delivery of two COVID-19 vaccine systems (from Pfizer/BioNTech and AstraZeneca/Oxford) and the recent approval of a third (Moderna) by the Medicines and Healthcare products Regulatory Agency (MHRA), it can be anticipated that soon all clinicians in primary and secondary dental care settings will have been offered a vaccination. We would like to warn that this may lead to a vaccine complacency centred around presumed immunization.

Each vaccine produces reportedly varying levels of immunity. Regarding the Pfizer/BioNTech vaccine, the efficacy has been reported at 95.0% after two doses.2 With the AstraZeneca/Oxford vaccine, the efficacy varies depending on dose regimens. Two standard doses reportedly yield 62.1% efficacy, whereas a low dose followed by a standard dose results in 90.0% protection.3 The Moderna vaccine, which is likely to be the next available, reportedly yields an efficacy of 94.1% following the second dose.4

Register now to continue reading

Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Up to 2 free articles per month
  • New content available

Already have an account? Sign in here